Gut microbiota influence metabolic syndrome, cancer, cardiovascular disease, and brain function through signaling molecules including GLP-1, prolactin-releasing peptide, and short-chain fatty acids.
Gut-to-brain peptide signalingGLP-1 and PrRP produced under gut microbiota influence travel via the vagus nerve to affect mood, cognition, appetite, and cardiovascular function
What the researchers found
The review highlights several key peptide-related signaling pathways influenced by gut microbiota:
- GLP-1: Activation of brainstem NTS by GLP-1 influences mood, cognition, and gastrointestinal motility
- Prolactin-releasing peptide (PrRP): Binds to PrRPR to suppress food intake and regulate stress, cardiovascular reactions, and circadian rhythms
- GPR119: Suppresses appetite with potential applications in type 2 diabetes and obesity treatment
- SCFAs interact with GPCRs, TLRs, and PPARs to influence inflammatory reactions, gut motility, hormone secretion, and neurochemical signaling
- Olfactory receptor OR51E1 influences blood pressure and vascular reactivity
- Butyrate binding to NF-κB and PPARγ regulates inflammation and prevents oxidized LDL uptake, reducing cardiovascular disease risk
Why it matters
The gut-brain axis and gut microbiome are revolutionizing our understanding of chronic diseases. This review connects the dots between gut bacteria and the peptide hormone signals they influence — providing the biological rationale for why microbiome-based interventions could treat conditions ranging from obesity to depression to heart disease.
How the study worked
Narrative review synthesizing animal and preclinical studies from PubMed, NIH, ScienceDirect, MDPI, Frontiers, Cell Press, and CAS Content Collection, focusing on gut microbiota signaling in metabolic syndrome, cancer, cardiovascular disease, and brain functions.
What this study cannot tell us
The review acknowledges that in-depth studies on how gut microbiota control cognitive behavior, mood, and neuropsychiatric disorders are lacking. Most evidence comes from animal and preclinical studies. The causal relationships between specific bacterial species and peptide signaling are not well established. Translation of microbiome findings to clinical interventions remains challenging.
How to read the evidence
This is a narrative review synthesizing primarily preclinical and animal evidence. While it provides a comprehensive overview of gut microbiota-peptide signaling, the clinical evidence for many discussed pathways remains limited.
When this study was published
Published in 2025, this review captures the current understanding of gut microbiota-peptide hormone interactions, a rapidly evolving field with increasing clinical relevance.
The bigger picture
This review sits at the intersection of microbiome science, peptide biology, and systems medicine. As we learn more about how gut bacteria control peptide hormone release, we can design better probiotics, prebiotics, and dietary interventions that target specific peptide pathways — potentially treating diseases through the microbiome rather than drugs.
Questions still open
- Can specific probiotic strains be engineered to enhance GLP-1 production for diabetes management?
- Does the gut microbiome explain individual variation in response to GLP-1 agonist drugs?
- Could microbiome-targeted interventions complement peptide hormone therapies?
Common questions
How do gut bacteria affect peptide hormones in your body?
Could changing your gut bacteria affect GLP-1 levels?
Read the original research
Key Signals Produced by Gut Microbiota Associated with Metabolic Syndrome, Cancer, Cardiovascular Diseases, and Brain Functions.
International journal of molecular sciences, 26(21)
Citation
Dicks, Leon M T. (2025). Key Signals Produced by Gut Microbiota Associated with Metabolic Syndrome, Cancer, Cardiovascular Diseases, and Brain Functions.. International journal of molecular sciences, 26(21). https://doi.org/10.3390/ijms262110539